Teva Agilect "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Teva/Eisai's Parkinson's therapy Agilect (rasagiline) is "approvable" at FDA, the firm announces July 5. The NDA, submitted August 8, 2003, covers use of the MAO-B inhibitor as monotherapy in early Parkinson's disease and as adjunct therapy to levodopa in moderate-to-advanced stages of PD. Teva is highlighting once-daily dosing (1Pharmaceutical Approvals Monthly Sept. 1, 2003, In Brief)...
You may also be interested in...
Teva rasagiline submission
Teva submits rasagiline NDA Aug. 8 for treatment of Parkinson's disease (PD). Rasagiline differs from other MAO-B inhibitors "in its chemical structure, its greater potency, lack of amphetamine metabolites and once-a-day dosing," the firm says. Somerset's Eldepryl (selegiline), the only approved PD drug in the MAO-B class, is administered twice daily. Teva will likely stress efficacy in the "off" period when PD symptoms are not adequately controlled. In the 18-week LARGO trial, rasagiline added to levodopa reduced "off" time by 1.2 hours daily or 21%. Rasagiline also significantly improved motor function based on the Unified PD Rating Scale in "on" and "off" states, while the comparator, Novartis' Comtan (entacapone), similarly improved scores in the "on" state but did not impact scores in the "off" state. Teva recently signed a co-promotion deal with Eisai; the firms are also developing the agent for Alzheimer's disease (1Pharmaceutical Approvals Monthly June 1, 2003, In Brief)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.